SCHEMBL1853671

SCHEMBL1853671

CC(C)(C)N(C(=O)O)C(C)(C)CCn1c(=O)oc2ccccc21

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.56
MAPK1 P28482 4/20 0.53
TSHR P16473 3/20 0.53
LMNA P02545 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
NPSR1 Q6W5P4 1/20 0.52
MEN1 O00255 1/20 0.52
RECQL P46063 1/20 0.52
KMT2A Q03164 1/20 0.52
MAPT P10636 2/20 0.51
HSD17B10 Q99714 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.50
POLB P06746 1/20 0.50
TP53 P04637 1/20 0.49
HPGD P15428 2/20 0.49
USP2 O75604 1/20 0.49
RAB9A P51151 1/20 0.48
MIF P14174 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4388370 0.79 ALDH1A1 (0.55) ALDH1A1MAPK1TSHRLMNASMN1; SMN2
SCHEMBL1853926 0.77 ALDH1A1 (0.62) ALDH1A1MAPK1TSHRLMNASMN1; SMN2
SCHEMBL3752895 0.75 SMN1; SMN2 (0.43) ALDH1A1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL738179 0.75 MEN1 (0.50) ALDH1A1MAPK1TSHRLMNASMN1; SMN2
SCHEMBL15292528 0.74 ALDH1A1 (0.71) ALDH1A1MAPK1TSHRLMNASMN1; SMN2
SCHEMBL2008321 0.74 MAPK1 (0.75) ALDH1A1MAPK1TSHRLMNASMN1; SMN2
Benzene SCHEMBL7861838 0.74 MAPK1 (0.75) ALDH1A1MAPK1TSHRLMNASMN1; SMN2
SCHEMBL5179294 0.73 MAPK1 (0.51) ALDH1A1MAPK1TSHRLMNASMN1; SMN2
SCHEMBL1858761 0.73 ALDH1A1 (0.56) ALDH1A1MAPK1TSHRLMNASMN1; SMN2
SCHEMBL23182640 0.73 MAPK1 (0.73) ALDH1A1MAPK1TSHRLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7939658-B2 Enantiomeric pure beta agonists, manufacturing and use as a medicaments thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-10 US disclosed
US-20100297028-A1 MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-25 US disclosed
US-7534789-B2 Enantiomeric pure β agonists, manufacturing and use as a medicament thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-19 US disclosed
US-20070249595-A1 Novel Enantiomeric Pure Beta Agonists, Manufacturing and Use as a Medicament Thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-25 US disclosed
US-20070203125-A1 Medicament Combinations for the Treatment of Respiratory Diseases BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249595-A1 Novel Enantiomeric Pure Beta Agonists, Manufacturing and Use as a Medicament Thereof ADRB1, ADRA1B, ADRA2B ALDH1A1 2222/4885MAPK1 2329/4885TSHR 573/4885
US-20070203125-A1 Medicament Combinations for the Treatment of Respiratory Diseases CHRM1, CHRM2, MTNR1B ALDH1A1 993/4885MAPK1 3939/4885TSHR 1644/4885
US-20100297028-A1 MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES CHRM1, CHRM2, MTNR1B ALDH1A1 993/4885MAPK1 3939/4885TSHR 1644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.